Navigation Links
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Date:6/16/2011

02/(ISSN)1097-0142/earlyview">http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142/earlyview.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,  

http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
3. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
4. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
5. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. ... company focused on obtaining FDA clearance and commercializing its ... announced the pricing of an underwritten public offering of ... to purchase 3,500,000 shares of its common stock at ... combined public offering price of $1.25 per share and ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
(Date:5/23/2013)... 2013 BioTrends Research Group, one of ... specialized biopharmaceutical issues, finds that, unaided, one in ... reported that in the past six months, they ... in anticipation of the next generation of HCV ... only 6 percent reported that they had begun ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... ... working in continuous flow chemistry processing, will deal with the application of the ReactIR flow ... of over 670 publications has been recognized with several prestigious prizes and awards, including most ... ...
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Healthcare Conference on Wednesday, November 11, at 9:30 a.m. ... may access a live webcast of the presentation on ... It is recommended that listeners log on 15 minutes ...
... 4 Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ... and webcast discussing the Company,s 2009 third quarter results on ... Flavin, Ph.D., Chairman & Chief Executive Officer, as well as ... update on the Company. A press release reporting the 2009 ...
Cached Biology Technology:Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... of Public Health at Emory University, along with ... received a $4 million grant over four years ... (Health and Exposome Research Center: Understanding Lifetime Exposures). ... awarded in the United States. , The ... of Environmental Health Sciences (NIEHS) of the National ...
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... of Allergy and Infectious Diseases (NIAID), part of ... a promising drug candidate attacks the bacterium that ... Proceedings of the National Academy of Sciences, the ... PA-824, which targets Mycobacterium tuberculosis (M. tb). ...
... Scientists at New York University School of Medicine report in ... that turns on the production of myelin, the fatty insulation ... the nervous system. The study, published in the September 1, ... avenue for treating nervous system diseases such as multiple sclerosis, ...
... could have a damaging effect on plant life, according ... Jersey Institute of Technology (NJIT). , The report, ... that nanoparticles of alumina (aluminum oxide) slowed the growth ... cucumber, cabbage, carrot and soybean. Alumina nanoparticles are commonly ...
Cached Biology News:NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3Scientists discover the molecular switch for nerve cells' insulating jelly rolls 2NJIT study shows nanoparticles could damage plant life 2
... Genome Amplification Kit utilizes a proprietary ... genomic DNA and conversion of the ... molecules flanked by universal priming sites. ... of the library molecules using universal ...
...
From formula-fed bovine calves Sterile, Cell culture tested...
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
Biology Products: